Physician profile
Nickolas Rongey
NPI 1982160990
$5,914.83
in general payments reported to CMS, 2019-2025
30 companies · $1,254 in 2025
The $1,254 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,014 · 2022: $1,224 · 2023: $1,158 · 2024: $1,265 · 2025: $1,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,676.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,658.69 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $394.37 | 2021-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $370.37 | 2021-2025 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $368.12 | 2021-2023 | Lifevest |
| Pfizer INC. | $305.00 | 2021-2025 | |
| Amgen INC. | $296.48 | 2021-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $288.54 | 2022-2025 | |
| Kestra Medical Technology Services, INC. | $284.57 | 2022-2025 | Assure Wcd |
| Impulse Dynamics (USA) INC. | $254.29 | 2022-2024 | Optimizer |
| Merck Sharp & Dohme LLC | $218.77 | 2021-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $188.27 | 2024-2025 | Camzyos, Eliquis |
| Abiomed | $164.30 | 2024-2025 | |
| Novo Nordisk INC | $164.23 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Cvrx, INC. | $160.95 | 2022-2025 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $160.18 | 2023-2024 | Inpefa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $113.96 | 2021-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $100.39 | 2021-2022 | |
| Scpharmaceuticals INC. | $87.41 | 2023 | |
| Esperion Therapeutics, INC. | $75.63 | 2023-2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $46.04 | 2024 | Arcalyst |
| Biobeat USA INC. | $31.91 | 2024 | Bb-613 Bpm Kit |
| Amarin Pharma, INC. | $30.05 | 2021 | |
| Abbott Laboratories | $24.55 | 2023 | Amplatzer Talisman |
| Actelion Pharmaceuticals US, INC. | $22.43 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $20.00 | 2023 | Arcalyst |
| Daiichi Sankyo INC. | $19.56 | 2023 | Injectafer |
| Kowa Pharmaceuticals America, INC. | $18.53 | 2021 | |
| Lilly USA, LLC | $18.39 | 2022 | |
| Boston Scientific Corporation | $15.66 | 2022 | |
| Vifor Pharma, INC. | $13.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nickolas Rongey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.